Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Switching to Azarga in Glaucoma Patients
NCT01484951Phase 4Completed
- Sponsor
- Alcon Inc.
- Start
- May 2011
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Azorga in open-angle glaucoma (OAG), ocular hypertension and pigmentary glaucoma (PG), sponsored by Alcon Inc. Primary endpoint: Change in Intraocular Pressure (IOP) at the Final Visit From Prior Beta-blocker Monotherapy (Timolol 0.5% Only) at Week 8. Started May 2011; status: completed.
02
Drugs
Azorga
03
Conditions
open-angle glaucoma (OAG)ocular hypertensionpigmentary glaucoma (PG)
Beyond the preview
Go deeper on NCT01484951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01484951.